COMBINED LISPRO AND SULFONYLUREA THERAPY IN TYPE II DIABETES MELLITUS

赖脯胰岛素和磺脲类药物联合治疗 II 型糖尿病

• 批准号: 3738894
• 负责人: MARK S FEINGLOS
• 金额: --
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3738894
• 关键词: combination chemotherapy; diabetes mellitus therapy; dosage; hormone analog; hormone therapy; human subject; human therapy evaluation; insulin; noninsulin dependent diabetes mellitus; sulfonylurea; combination chemotherapy; diabetes mellitus therapy; dosage; hormone analog; hormone therapy; human subject; human therapy evaluation; insulin; noninsulin dependent diabetes mellitus; sulfonylurea

The purpose of this study is to assess the effects of combination therapy with sulfonylureas and a new human insulin analog, LYSPRO, in patients with type II diabetes who are poorly controlled on the maximum dose of their current sulfonylurea.

这项研究的目的是评估联合疗法的影响 患者使用磺酰氟菌和新的人类胰岛素类似物Lyspro 与II型糖尿病的最大剂量受到控制不佳的II型糖尿病 他们目前的磺酸盐。